Stocks to Watch For: R.R. Donnelley & Sons Company (NASDAQ:RRD), Intellia Therapeutics Inc. (NASDAQ:NTLA)

1

R.R. Donnelley & Sons Company (NASDAQ:RRD)

R.R. Donnelley & Sons Company (NASDAQ:RRD) represented a move of 1.77 percent or $-0.28 per share and closed its previous day trading session at $6.9. 839663 Shares were traded in the last trading session with an Average Volume of 773.41 Million Shares. The stock currently has a Market Capitalization of 491.83 Million.

RR Donnelley is a leading global provider of integrated multichannel marketing and business communications solutions. The company helps the customers communicate more efficiently and effectively as they use words and images to inform, educate, entertain and sell. In each of the businesses, the company uses the distinctive capabilities to manage and distribute words and images in ways that provide the greatest value to every customer. RR Donnelley offers a comprehensive portfolio of capabilities, experience and scale that enables organizations around the world to effectively create, manage, deliver and optimize their multichannel communications strategies. RR Donnelley’s innovative technologies enhance digital and print communications to deliver integrated messages across multiple media to highly targeted audiences at optimal times for clients in virtually every private and public sector.

The stock traded between $ 6.51 and $18.52 over 1-Year time period showing its price to sales ratio of 0.07. R.R. Donnelley & Sons Company (NASDAQ:RRD) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-21.74 and 200-Day Simple Moving Average of $-32.23. Its Price to Free Cash Flow is 0 and Price to Book of 0.

Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, R.R. Donnelley & Sons Company (NASDAQ:RRD) reported its Actual EPS of $0.3/share. The analysts offering Earnings Estimates for the company were believing that R.R. Donnelley & Sons Company could bring EPS of $0.29/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus showing an Earnings Surprise of 3.4 Percent.


Intellia Therapeutics Inc. (NASDAQ:NTLA)

In the last trading session, Intellia Therapeutics Inc. (NASDAQ:NTLA) added its value by 5.13% closing at the price of $25.8. The stock currently has market capitalization of 1.08 Billion, with average volume of 892.98 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Intellia Therapeutics Inc. (NASDAQ:NTLA) is showing beta of 0. This particular value of beta suggests that Intellia Therapeutics Inc. (NASDAQ:NTLA) has historically moved 0% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Intellia Therapeutics Inc. (NASDAQ:NTLA) is at $-1.55.

The stock currently has RSI of 60.87. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.

Intellia Therapeutics Inc. (NASDAQ:NTLA) topped its 52-week high price of $33.34 on 10/31/17 and 52-Week Low Price of $10.83 on 05/31/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 10.13% and monthly volatility of 8.81% respectively.